CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Clinical Cancer Research. The paper, entitled “CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacological properties for cancer therapy,” will also be published in the print version of this journal shortly.
